144 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
License Application (sBLA) for Dupixent as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD … in asthma for children aged 2 to 5 years was initiated.
In February 2024, the MHLW in Japan approved Dupixent for the treatment of chronic
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
Dupixent sBLA for chronic obstructive pulmonary disease (COPD) with type 2 inflammatory phenotype and linvoseltamab BLA for multiple myeloma submitted … (second half 2024)
Report results from ongoing Phase 3 study for Dupixent in chronic spontaneous urticaria (CSU) in biologic-naïve patients (fourth quarter
8-K
EX-99.1
h99w hp6x1zl
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
ay3lxz4jgb bjo7zytpt
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
8-K
EX-99.1
nedzrlsaobqj4v1amb
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-99.1
yvxlpl 48f
4 May 22
Regeneron Reports First Quarter 2022 Financial and Operating Results
7:08am
DEFA14A
e9kfy4 c6
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-99.1
huyyij f5
4 Feb 22
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
7:29am